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ARTICLE
Dual RNA-seq identifies human mucosal immunity
protein Mucin-13 as a hallmark of Plasmodium
exoerythrocytic infection
Gregory M. LaMonte1, Pamela Orjuela-Sanchez1, Jaeson Calla1, Lawrence T. Wang1, Shangzhong Li1,2,3,
Justine Swann1, Annie N. Cowell4, Bing Yu Zou1, Alyaa M. Abdel-Haleem Mohamed5,
Zaira Hellen Villa Galarce6, Marta Moreno6,7, Carlos Tong Rios6, Joseph M. Vinetz4,6,8, Nathan Lewis1,2,3 &
Elizabeth A. Winzeler1
The exoerythrocytic stage of Plasmodium infection is a critical window for prophylactic
intervention. Using genome-wide dual RNA sequencing of flow-sorted infected and unin-
fected hepatoma cells we show that the human mucosal immunity gene, mucin-13 (MUC13),
is strongly upregulated during Plasmodium exoerythrocytic hepatic-stage infection. We con-
firm MUC13 transcript increases in hepatoma cell lines and primary hepatocytes. In immu-
nofluorescence assays, host MUC13 protein expression distinguishes infected cells from
adjacent uninfected cells and shows similar colocalization with parasite biomarkers such as
UIS4 and HSP70. We further show that localization patterns are species independent,
marking both P. berghei and P. vivax infected cells, and that MUC13 can be used to identify
compounds that inhibit parasite replication in hepatocytes. This data provides insights into
host-parasite interactions in Plasmodium infection, and demonstrates that a component of
host mucosal immunity is reprogrammed during the progression of infection.
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Malaria remains a significant global health problem with214 million annual cases and up to a half million deathsin 20151. The disease, caused by protozoan parasites of
the genus Plasmodium, is transmitted when a female Anopheline
mosquito takes a blood meal and injects infectious Plasmodium
sporozoites. These sporozoites (typically less than 100) migrate to
the liver where they invade hepatocytes. This exoerythrocytic
infection develops asymptomatically in the infected hepatocytes
over a period of 2–10 days, depending on the species of malaria
parasite. The merosome released from the infected hepatocyte
eventually bursts2, releasing tens of thousands of merozoites that
are programmed to infect erythrocytes. The repeated infection
and lysis of erythrocytes results in symptomatic disease, and for
this reason, the erythrocytic stage has been the historical focus of
drug discovery. On the other hand, the exoerythrocytic stage
attracts attention due to the substantially reduced parasite bur-
den. Unsurprisingly then, most malaria vaccine candidates (such
as RTS,S/AS013, also known as Mosquirix) target the exoery-
throcytic stage for this reason. In addition, while malaria is
typically prevented through the use of insecticide-treated bed nets
and treated with chemotherapy such as artemisinin combination
therapies, there is a recognized need for new molecules that may
protect against malaria and which might be formulated as a
component in a Single Exposure, Radical Cure, and Prophylaxis
medicine that could be used in a malaria-elimination campaign4.
From the perspective of host–parasite interactions, there are
likely numerous possible host targets for therapeutic intervention.
During the initial stage, the infected hepatocyte undergoes sig-
nificant alteration yet does not undergo apoptosis. The parasite’s
metabolic needs are also likely to be considerable, given that one
sporozoite can yield over 30,000 merozoites within a single
infected host cell. It thus seems very likely that the parasite is
releasing effectors into the host cell to control host cell behavior.
This notion that the malaria parasite is modifying host–gene
expression is heavily supported by studies in the related api-
complexan parasite, Toxoplasma gondii. Gene-expression studies
in T. gondii have been used effectively to characterize the host
response to infection, due to its high multiplicity of infection5,6.
As observed in these studies, the parasite must carefully regulate
immune activation and host–cell effector mechanisms (reviewed
in ref. 7) to establish infection. It is now known that multiple
proteins, including ROP18 kinase8,9 and GRA1510, are secreted
into the host cell, altering host cell signal transduction and
inflammation11.
In contrast to Toxoplasma, relatively little is known about
molecules produced by hepatocytes in response to Plasmodium
sporozoite infection, in part because of the difficulty associated
with studying the exoerythrocytic stage (reviewed in ref. 12).
Plasmodium sporozoites form a parasitophorous vacuole within
infected hepatocytes. Parasite infection is known to rely on
multiple host molecules, including EphA2 and CD81, which have
been shown to be essential for hepatocyte invasion13,14. Parasite-
secreted molecules include LISP and IBIS1, which are secreted
into hepatocytes in the Plasmodium berghei model15,16. Another
candidate effector molecule is the circumsporozoite protein
(CSP), an abundant protein that is shed from the parasite
sporozoite surface. It was also shown that expression of recom-
binant CSP in HeLa cells regulates TNF-alpha dependent
host–immune signaling and NF-ḳB translocation to the nucleus,
for example17.
As with Toxoplasma, global gene-expression analysis of infec-
ted cells should be an effective way to identify host genes that play
a role in Plasmodium exoerythrocytic infection. However, the low
parasite to hepatocyte ratio also creates a low signal to noise ratio.
This problem can be overcome using dual-RNA sequencing of
flow-sorted infected host cells18, which analyzes host and
pathogen transcriptomes simultaneously. In addition, the tre-
mendous depth of coverage offered by current transcriptomic
sequencing approaches allows for a deep examination of the data.
Here, we have taken advantage of this dual-RNA sequencing
approach in order to gain insights into Plasmodium liver-stage
development. We have identified and partially characterized one
host-factor, Mucin13, which is highly upregulated during
host–cell infection by both P. berghei and Plasmodium vivax. In
contrast to previously identified parasite markers of liver-stage
infection, such as HSP70 or UIS419. Mucins, as a component of
the mucosal immune system, serve a critical role in host innate
immune defenses as an initial barrier to infection. MUC13, as one
of the transmembrane mucins, has been shown to play important
roles in defense against several forms of cancer20 and bacterial
infections, such as those caused by Helicobacter pylori21. Mucosal
immunity has not been shown to have a significant role in
malaria (reviewed in ref. 22), in part because most research is
focused on the asexual blood stage. However, in this study, we
display a novel interaction of innate immunity against parasite
infection. Therefore, MUC13 may serve as a universal biomarker
for Plasmodium infection, upregulated regardless of the species of
infecting malaria parasite.
Results
Plasmodium infection significantly alters gene expression. To
investigate host–pathogen interactions in Plasmodium exoery-
throcytic stages, we conducted a dual RNA sequencing study, a
strategy that has proven useful in identifying novel interactions in
other intracellular parasitic organisms, including T. gondii and
Leishmania major23–25. We initially used P. berghei, a cause of
murine malaria, to infect the hepatoma cell line, Huh7.5.1, which
had proven to be readily sortable using flow cytometry26. The
Huh7.5.1 hepatocytes were first infected in vitro with P. berghei
sporozoites expressing green fluorescent protein (GFP) regulated
by an elongation factor-1α promoter27 that is active throughout
the 48-h liver-stage infection26. Samples were collected at time 0
(uninfected hepatocytes and sporozoites before infection), 24 and
48 h postinfection (hpi), then infected and uninfected cells were
separated using fluorescence-activated cell sorting. Altogether,
approximately 10,000 cells of each type were collected, and sub-
jected to a pilot study in which we determined that obtaining 20
million reads at 24 hpi, or 10 million reads at 48 hpi, would be
sufficient to obtain an average 50× coding genome coverage for
both host and P. berghei (Supplementary Figure 1). Huh7.5.1
experiments with 10,000 infected cells were then conducted in
triplicate on three different days. To ensure that our expression
patterns were not dependent on the human cell line used, we
collected additional experiments with HepG2-CD81 cells (48 hpi
infected and uninfected) and HC04 cells (2 × 48 hpi infected and
uninfected), both additional human hepatocyte cell lines able to
support P. berghei infection28. Total RNA was isolated from the
different populations and dual RNA-sequencing performed for
both P. berghei and the host human hepatocyte-derived cell lines
at each time point. Over 978 million total reads were obtained
and aligned to either the P. berghei reference genome or the
human reference genome, 72.8% (80.8% if not including spor-
ozoite only samples) of which map to either the human or P.
berghei genomes (Supplementary Data 1).
Altogether we detected transcripts with at least one sample
having >10 reads for 21,941 of the 58,051 human genes and 4770
of the 5245 parasite genes (Parasite Read Counts—Supplementary
Data 2, Human Host Read Counts—Supplementary Data 3).
Principle component analysis showed, strong separation of the
different cell types, but that expression patterns were generally
consistent across experimental replicates (R2= 0.86–0.89).
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Although our ultimate goal was to identify host biomarkers
of infection, we first analyzed the gene-expression patterns for
P. berghei as a control to ensure that our time point
accurately reflected the expected parasite biology. In the
parasite RNA sequencing data, PBANKA_050120 (UIS4) and
PBANKA_040320 (CSP) were the most highly expressed
within sporozoites (Supplementary Data 2). In contrast,
PBANKA_071190 (HSP70) and PBANKA_100300 (LISP2), were
the most highly expressed at 48 hpi (Supplementary Data 2). All
are well-validated hepatic-stage markers15,29.
As anticipated, parasite gene-expression changes followed
known patterns, including downregulation of genes at 48 hpi
(relative to sporozoites only) with known sporozoite function,
such as CSP (log2FC of −9.6, p value 3.61 × 10−109), CELTOS
(log2FC of −12.3, p value 3.70 × 10−78), and UIS4 (log2FC of
−9.3, p value 9.32 × 10−219), combined with upregulation at 48
hpi of merozoite genes such as MSP1 (log2FC of 3.8, p value
2.78 × 10−25), MSRP2 (log2FC of 6.6, p value 8.22 × 10−23), and
SERA1 (log2FC of 5.0, p value 2.84 × 10−46) (Supplementary
Data 4)30. We also observed excellent concordance between our
P. berghei expression data and reported P. falciparum quantitative
microarray gene-expression studies, with the P. falciparum
homolog of 5 of the 10 most highly expressed P. berghei
sporozoite transcripts (by read count at 0 hpi) also being among
the 10 most highly expressed P. falciparum transcripts (CSP,
ETRAMP10.3/UIS4, TRAP, CELTOS, and HSP70—hypergeo-
metric mean probability of association by chance < 1.51 × 10−12)
(Supplementary Data 2)31. In addition, 13 of the 20 most
highly expressed P. falciparum sporozoite transcripts from that
study31 possessed homologs that were also highly expressed
(within the top 100 genes) in our P. berghei dataset at 48 hpi
(p value < 2.82 × 10−18) (Supplementary Data 2), demonstrating
that the sporozoite transcriptional profile is largely shared
between rodent and human Plasmodium species regardless of
the experimental platform.
Interestingly, we observed less correlation between our studies
and previous transcriptomic studies of Plasmodium yoelii liver-
stage parasites obtained directly from disassociated, infected
mouse livers and analyzed using ratiometric two color 65-mer
microarrays30. Examining the transition from 24 to 48 hpi (this
study) and 24 to 50 hpi (P. yoelii), and ranking genes with data
and with syntenic orthologs (1383 genes) in both species by fold
change gave a Spearman rank correlation coefficient of only 0.022
(Supplementary Data 2). There were some similarities including
the induction of Liver-Specific Proteins 1 and 2 in both datasets,
although our data show a > 300X average log2FC at 48 hpi for
PBANKA_1003000 (LISP2), vs. a log2FC of 1.7× for PY04387 in
theirs. Another similarity was the strong induction of an
uncharacterized gene (PY01013 and PBANKA_0519500) ranked
at number 1 and 4, respectively in the two datasets (Supplemen-
tary Data 2). Although some differences are clearly platform-
dependent (e.g., RNAseq vs. two-color spotted microarrays,
which have a smaller linear range30) there may be differences in
the biology. For example, many of the most highly induced genes
in our 48-h dataset relative to 24-h had roles in merozoite
function (e.g., MSP1, PBANKA_0831000, ranked 7 in our P.
berghei dataset, and 1246 (of 1383)) in the P. yoelii dataset
(Supplementary Data 2). Likewise, MSP7-like
(PBANKA_1349000), ranked 1 in P. berghei and 1006 in P. yoelii
(Supplementary Data 2), suggesting a slightly later stage of
development at time of sampling for our dataset and potentially
tighter synchronization for our in vitro study.
On the other hand, we found better concordance with the
Tarun proteomic analysis30 (Pearson correlation= 0.68) (Supple-
mentary Data 2). The most abundant transcripts in our 48-h P.
berghei RNAseq dataset corresponded to the genes with the most
abundant spectra in the P. yoelii dataset. For example, 14 of the
30 top-ranked syntenic genes were shared between our 48-h
RNAseq dataset (average at 48 hpi for Huh7.1) and the 40-h
Tarun liver-stage proteomic dataset (p value 2.1 × 10−11,
hypergeometric mean test), despite the data coming from
different species and different methods (Supplementary Data 2).
Notably MSP1 was also highly expressed in the Tarun late-stage
liver proteomic dataset (in contrast to the transcription study),
ranking 16 out of 689 proteins in terms of spectra count at 50 hpi
(Supplementary Data 2).
After having demonstrated the validity of the experimental
design, we turned our focus to our primary goal, the identification
of host-factors involved in parasite development. In order to
broadly examine host–cell gene-expression patterns, we first
identified differentially expressed genes using pairwise compar-
isons between infected and uninfected cells focusing primarily on
the 48-h time point (which was sampled with multiple hepatocyte
lines) (Huh7.5.1 cells alone—Supplementary Data 4, all three cell
lines (Huh7.5.1, HC04, and HepG2) combined at 48 H—
Supplementary Data 5). The expression profiles were next
subjected to hierarchical clustering (Fig. 1a, Supplementary
Data 3). The data showed, as predicted by principle component
analysis, that there were dramatic differences between the
different cell lines. However, subclusters could be identified that
revealed genes that were consistently upregulated across cell lines
with the most dramatic changes occurring 48 hpi.
In order to first classify the gene-expression changes, we
determined whether specific functional classes were overrepre-
sented in up and downregulated genes. Analysis of the 21,941
detected genes at the 48-h time point showed that 840 human
genes were upregulated (average > 2× change between pairs, p
value < 0.01) and 618 were downregulated using similar criteria
(Supplementary Data 6 and 7). The sets of upregulated genes were
compared to compiled lists of genes with known functions,
including gene ontology groups, using Metascape32. We found that
genes involved in host ribosome function (p value 3.23 × 10−14),
and DNA replication (p value 3.46 × 10−10) were downregulated
(Supplementary Data 6), indicating that the host cell has
decreased the production of ribosomes and DNA replication
machinery as it is presumably no longer dividing. The most
strongly downregulated gene, ENHO, plays a role in the positive
regulation of Notch signaling (Energy Homeostasis related,
−4.34× average Log2FC, p value 1.11 × 10−08). The chemokine
ligand, CXCL10, which is a hallmark protein in the JAK-STAT,
and alpha and gamma interferon pathways, was also highly
downregulated (−2.88 Log2FC, p value 4.68 × 10−05), as was
thymidine kinase, a gene involved in DNA synthesis. Further
analysis of dysregulated transcriptional pathways using an
independent pathway analysis algorithm (Ingenuity pathway
analysis33) in order to confirm the previous analysis, also
indicated downregulation of the eIF2 signaling (Supplementary
Figure 2).
The 840 upregulated genes were more difficult to classify.
Transcript increases were observed for genes that play a role in
general transcriptional pathways (Generic Transcription Pathway
—p value 2.0 × 10−6), as well as genes with a role in the regulation
of energy homeostasis (p value 1.32 × 10−4) with enrichment in
adipocytokine signaling pathway and gluconeogenesis, among
others (Supplementary Data 7). These changes are presumably a
reflection of the metabolic changes the host cell needs to make to
support rapid parasite growth and replication. We also observe
strong upregulation of mTOR signaling, whose upregulation has
been shown to be necessary for hepatic development34, using
Ingenuity pathway analysis. The most highly upregulated gene,
however, was the human mucosal innate immunity gene, Mucin13
(MUC13, average 16.51 upregulation, p= 7.84 × 10−51), a gene
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which is also upregulated at the mRNA level in response to H.
pylori infection or IL-1β stimulation of MKN7 cells35 or treatment
with the colitis-inducing agent, dextran sodium sulfate36.
MUC13 is upregulated during parasite hepatic infection.
Because Mucin13 (MUC13) transcripts are found in some cancers
including ovarian and colorectal cancers37 we next sought to
confirm that this was not an artifact of using immortal hepatoma
cells. We, therefore validated, using quantitative reverse tran-
scription polymerase chain reaction (PCR), upregulation of the
clearest example of an infection status marker gene (Fig. 1b),
MUC13, in P. berghei-infected primary human hepatocytes, as
well as in P. berghei-infected Huh7.5.1, HepG2, and HC04 cells.
In addition, we validated several additional genes (SLC22A8,
RASSF9, and NEAT1) which were highly upregulated in
Huh7.5.1 cells, yet not within this infection responsive cluster, as
controls. In these four cell lines, we observed that only MUC13
mRNA was consistently upregulated (~16×) (Fig. 1c).
MUC13 encodes a membrane bound mucin with abundant O-
and N-glycosylation on its extracellular domain (Schematic:
Fig. 1d) as well as EGF domains and has a molecular weight of 54
kDa. To test whether we also observe upregulation of the MUC13
protein we performed western blot analysis using a commercially
available polyclonal antibody that recognizes the C-terminal
domain (Fig. 1d). Interestingly, MUC13 has been reported both
as a 54 kDa transmembrane protein and a putative, smaller 33
kDa soluble form in which the transmembrane domain has been
cleaved38. We clearly observed the 54 kDa form (Fig. 1e),
although we did not observe the lower molecular weight product
(Supplementary Figure 3), indicating that the N-terminal
extracellular domain may remain attached. In addition to
recognizing the correct band, the MUC13 antibody showed
protein upregulation in infected Huh7.5.1 and HC04 cells
(Fig. 1e), compared to uninfected co-sorted controls that were
exposed to identical culture conditions.
MUC13 colocalizes with parasites during hepatic development.
To assess whether MUC13 colocalizes with parasite in infected
hepatocytes, we used two independent MUC13 antibodies
(Antibody #1: AbCam #Ab65109, Antibody #2: LifeSpan BioS-
ciences #LS-C345092 (discontinued)), including the antibody
described above, and two independent parasite antibodies that
react with heat-shock protein 70 kDa (HSP70) and upregulated-
in-sporozoites 4 (UIS4) (Fig. 2, Supplementary Figure 4). These
two parasite antibodies stain the cytoplasm of developing
exoerythrocytic form (EEF) schizonts39 and the parasite para-
sitophorous vacuolar membrane40, respectively. Our immuno-
fluorescence (IFA) analysis showed that our MUC13 antibody
recognized only parasite-infected cells. Interestingly, MUC13 is
typically expressed on the outer cell membrane of host mucosal
epithelial cells41 where it is found on apical membranes and
forms part of the glycocalyx that presumably protects gut cells
from pathogens. However, in parasite-infected cells the staining
(Fig. 2, Supplementary Figure 4) largely colocalized with
cytoplasmic parasite HSP70 (Supplementary Figure 4) and inside
of UIS4 (Fig. 2), indicating that this host protein may be actively
transported into the parasite cytoplasm. Although the cyto-
plasmic localization is surprising, it reflects the documented
behavior of this protein in cancerous cells. It has been shown that
MUC13 is cytoplasmic and overexpressed in metastatic colon
cancer cells but apically located in normal adjacent control cells42.
In addition, MUC13 is translocated from the apical membrane to
the cytoplasm in colonic epithelium cells after treatment with the
colitis-inducing agent, dextran sodium sulfate36. While this could
be due to acquired cross-reactivity in stimulated cells, MUC13
antibodies reveal no MUC13 staining in knockout animals36.
Although the apparent localization within the parasite cytoplasm
could indicate cross-reactivity with parasite proteins, we found
that MUC13 IFA levels closely correlate with transcript levels. We
observed almost no MUC13 transcripts in our RNAseq at time
zero and an IFA time course also showed no MUC13 staining at
two hpi, during which time parasites were present and could be
readily detected by HSP70 antibody staining (Fig. 3). The
intensity of MUC13 staining was also directly proportional to
MUC13 RNA levels, with a very modest induction at 24 hpi, and
increasing to strong induction at 48 hpi (Fig. 3). This induction of
MUC13 also seems to be specific to exoerythrocytic infection, as
IFA analysis for MUC13 in asexual blood stage parasites (with
MUC13 Antibody #2—LifeSpan Biosciences #LS—C345092)
shows no colocalization with parasites, only a faint MUC13 signal
along the RBC membrane (Supplementary Figure 5). In addition,
staining with a third, independently derived, commercial rabbit
polyclonal antibody to the MUC13 extracellular domain (MUC13
Antibody #3—LifeSpan BioSciences #LS-A8191) showed nearly
identical co-staining patterns (Supplementary Figure 6) to the
other two antibodies.
A significant concern remained whether MUC13 was a marker
for human malaria infection, or was simply limited to the rodent
model. In order to validate the utility of MUC13 as a marker of a
human malaria infection, we next examined the subcellular
localization of MUC13 in cells infected with the human parasite,
P. vivax. Symptomatic P. vivax malaria patients were recruited
from the Loreto region of Peru using an approved human
subjects’ protocol and asked to provide a blood sample. This
patient blood was washed and used to feed colonized female
Anopheles darlingi mosquitos43 using a standard membrane-
feeding assay. After 14 days, salivary glands were dissected and
the resultant sporozoites were harvested and incubated with
HC04 cells for 7 days. IFA microscopy demonstrated that
MUC13 also colocalizes very strongly with P. vivax HSP70 in
HC04 cells (Supplementary Figure 4), indicating that MUC13 is a
marker of human malaria infection as well. Similar to the rodent
parasite, MUC13 signal covers the parasite, as would be observed
if MUC13 is localized to the cytosol and nuclear membrane of
developing merozoites of the developing exoerythrocytic parasite.
MUC13 is a quantifiable host marker of parasite infection.
Species-specific parasite antibodies are typically used in liver-
Fig. 1 Identification of differentially expressed host and parasite transcripts. a Hierarchical clustering of RNAseq samples based on gene-expression
patterns in the indicated host hepatocytes and specified times postinfection. The color scale for the figure, as indicated by the scale bar in the lower left
corner of Fig. 1a, indicates log2 fold changes from −3 to +3. Data used to generate heatmap is located within Supplementary Data 3. b Volcano plot of
gene-expression pattern vs. p value, with the position of MUC13 indicated. c Confirmation of host factor upregulation via qPCR, with relative quantitation of
the indicated host transcripts calculated using the ΔΔCT method, in the indicated hepatocyte cell types (data presented as mean ± s.e.m, n= 3 with
individual biological replicates overlaid, *= p value < 0.05, ***= p value < 0.001. p values determined by two-tailed t test). d Schematic of MUC13 protein
structure and approximate antibody locations. Antibody #1: AbCam #Ab65109, Antibody #2: LifeSpan BioSciences #LS-C345092 (discontinued), and
Antibody #3: LifeSpan BioSciences #LS-A8191. e Confirmation of MUC13 upregulation during infection via western blot
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stage imaging assays to measure parasite killing in response to
drug candidates28. To assess whether MUC13 antibodies could be
used as a substitute for parasite antibodies in imaging assays, we
performed automated microscopy on P. berghei and P. vivax
infected cultures after staining with parasite and the MUC13
antibody. HsMUC13 antibodies indicated nearly identical levels
of parasitemia relative to parasite HSP70 (Fig. 4a). The value of
MUC13 for parasite detection was also seen in dose response
testing, as MUC13 was able to detect the decrease in parasite
levels after dose-titration with two control compounds, atova-
quone and puromycin (Fig. 4b), which yielded EC50 values
equivalent to those determined using parasite HSP70 (Fig. 4c).
Similar compound responses were also observed between HSP70
and MUC13 in parasites treated with compound at 12 and 24 hpi
(Supplementary Figure 7). The fluorescent signal from MUC13
antibody staining clearly demonstrates the effect of atovaquone
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upon parasite growth, as P. berghei parasites treated with atova-
quone very early in the P. berghei lifecycle (2 hpi, when atova-
quone is most effective26) demonstrate a marked decrease in size
(Fig. 4d) and infection rate when compared with later or no drug
treatment. This also indicates that the MUC13 induction begins
prior to 48 hpi, since parasites treated with a lethal dose of ato-
vaquone at 12 hpi still exhibit MUC13 expression. These data
show that MUC13 can substitute as a biomarker of parasite
hepatic infection in drug discovery assays.
Although theMUC13 gene can be disrupted in mice it has been
shown, nevertheless, to protect human epithelial cells against
inflammation by inhibiting cellular apoptosis20. To determine
whether MUC13 may play a role in Plasmodium survival and
persistence, we used two parallel approaches to inhibit MUC13: a
traditional stable pooled shRNA approach, delivered by lentivirus,
to independently knockdown human MUC13 in both HC04 and
Huh7.5.1 cells; and CRISPR/Cas9 to knockout MUC13 in clonal
HC04 cell lines. The shRNA approach generated an observed 60%
knockdown in MUC13 protein levels (Fig. 5a), while the
knockout approach yielded multiple clones exhibiting no
MUC13 protein expression (Fig. 5a). Stable MUC13 knockdown
and knockout HC04 cells were established, and when infected
with P. berghei parasites expressing luciferase, we observed no
decrease in either parasite load (via luciferase) or parasite number
(via flow cytometry) at 48 hpi (Fig. 5b). This lack of decrease in
parasite number likely indicates that MUC13 is not required for
parasite growth in vitro, suggesting that it may play a role in vivo,
potentially during merosome release or to assist in immune
invasion. Imaging of parasites infecting shMUC13 knockdown or
knockout cells by IFA (Fig. 5c) indicated that the MUC13
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antibody is specific for the protein, as staining in both the
parasites and in the surrounding infected cell.
Discussion
As the goal of malaria eradication moves forward, the need for
biomarkers to identify individuals infected with malaria without
clinical symptoms will be essential. Our data illustrate the
importance precise synchronization and deep sequencing, the
lack of which may mask differences. For example, Albuquerque
et al.44 had previously performed a microarray-based study using
infected mouse livers at 40 hpi using P. yoelii, as well as P. berghei
infection of the mouse cell line, Hepa1–6 at 24 hpi, and showed
relatively few genes that were consistently changed between the
species and time points.
Likewise, another very recent study also used several
fluorescence-activated cell sorting (FACS)-sorted hepatocyte cell
lines and GFP-expressing P. berghei and identified Aquaporin 3
as differentially expressed in HepG2 cells at 24 hpi45. Our data
also showed significant upregulation of Aquaporin 3 at 48 hpi in
HepG2 cells and HC04 cells (Supplementary Data 4). Likewise,
their study observed upregulation of Mucin 13 during late-stage
parasite development. Despite being one of the most highly
upregulated genes in their study (ranked 4 when considering
18,720 genes that were analyzed in both studies) it was not 1 of
the 5 genes considered statistically significant in the RNAseq
analysis of 48 hpi Huh7.5.1 cells (adjusted p value = 0.63 in their
study, vs. adjusted p value = 1 × 10−53 in ours). The fact that very
few genes changed to a level that reached statistical significance in
this study (vs. > 3000 with an adjusted p value of less than 0.05
and a fold change of greater than 2 in ours) could also be due to
experimental variation across their replicates, loss of synchroni-
zation, or potentially sample processing differences.
Interestingly, we found some notable similarities with an earlier
study which focused on timepoints at 30, 60, and 180 min post-
infection in human cells46. This study compared bulk (not flow-
sorted) human HepG2-A16 cell responses after infection with
irradiated and nonirradiated Plasmodium falciparum sporozoites
as well as after exposure to salivary gland material. Systematic
searches showed that a number of genes that they showed were
changing between conditions were also changing between con-
ditions in our study. Of the 742 differentially expressed
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transcripts listed in this manuscript, 662 transcripts had clear
matches in our dataset and of these 256 transcripts were differ-
entially regulated in our dataset (p value < 0.001). Of the 24,550
transcripts analyzed in this study, 5934 transcripts have adjusted
p value of less than 0.001. The probability of this overlap (256 of
665 transcripts) occurring by chance is 3.21e−17. Perhaps not
unexpectedly, in ~half the cases (131), the changes were in dif-
ferent directions. It is important to consider, that the authors
were mostly looking at the expression profiles of uninfected cells,
after sporozoite addition, because uninfected cells will outnumber
infected ones in a bulk culture by 100:1. The group showed, for
example, that thymidine kinase (TK1) was strongly induced in
their sporozoite-treated bulk culture at 2 hpi relative to mock-
treated, salivary gland control (p value < 1 × 10−7, 3× increase in
sporozoite-treated bulk cultures), but we show this induction was
likely occurring in the noninfected flow-sorted cells, vs. the infected
flow-sorted cells at 48 hpi (adjusted p value= 1.06 × 10−18, 3.5×
decrease in infected). These data highlight that the human
response to parasite infection is likely to be conserved, regardless
of parasite species.
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Fig. 5 Confirmation of antibody specificity in regards to HsMUC13’s localization within P. berghei during liver-stage infection. a Confirmation of both MUC13
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knockdown and knockout in the indicated cells infected with P. berghei expressing either luciferase (measured via total luminescence) or GFP (measured by
FACS). Data is presented as mean ± s.e.m with n= 3 with individual biological replicates overlaid. c Confocal microscopy images of HC04 liver cells, either
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One concern with immune-localization studies is the specificity
of the MUC13 antibody signal, which colocalizes with the Plas-
modium parasite by IFA microscopy and could be due to cross-
reactivity with glycosylated parasites proteins that are only present
at 24–48 hpi. This is unlikely due to multiple independent lines of
experimental evidence. First, the signal from the MUC13 antibody
is sensitive to both shRNA knockdown and CRISPR/Cas9
knockout, both of which have been used by others study MUC13
phenotypes47. Second, we observe no MUC13 mRNA during early
hepatocyte infection (2 hpi) (Fig. 3) or asexual blood stage infec-
tion (Supplementary Figure 5), but do detect strong parasite
HSP70 signal later during exoerythrocytic development. In addi-
tion, at intermediate points of infection (12 and 24 hpi), the
MUC13 IFA intensity correlates with the dramatic transcriptional
induction of MUC13 during late-stage hepatic infection. In addi-
tion, the increased level of MUC13 protein within the parasite, as
compared to neighboring uninfected host cells (Figs. 2, S4, S6), is
consistent with the 50-fold (for Huh7.5.1) induction of MUC13
transcript levels in infected cells at 48 hpi. Third, the pattern of
MUC13 expression we observe, both in host cell and parasites, is
consistent with previously reported studies of MUC13 localiza-
tion20, displaying a speckled pattern with cytoplasmic and nuclear
staining in cancer cells but apical in normal epithelial cells41.
Fourth, we find similar staining with two independently derived
MUC13 antibodies that recognize different areas of the protein.
Fifth, similar MUC13 localization is observed with different
parasite species. Lastly, our western blots (Supplementary Fig-
ure 3) do not indicate additional binding to products other than
the slightly greater than 50 kDa band expected for MUC13. Our
data, as well as published data, thus strongly support
MUC13 specificity for both of our tested MUC13 antibodies.
How MUC13 is trafficked to the parasite cytoplasm and
nucleus is an open question. Other membrane-based mucins are
packaged into secretory vesicles that are targeted to the site of
infection and it is possible that similar localization methods are
being used here. It is possible that in other systems MUC13 is
exported to the site of infection but is not observed in micro-
graphs because this space is extracellular and protein can be
washed away. Cytoplasmic and nuclear localization of MUC13 is
observed in cancer cells however, where MUC13 is over-
expressed37, so potentially a similar process of MUC13 inter-
nalization is at play here. However, in our case the protein is
contained inside the parasitophorous vacuole of the parasite.
Mutagenesis of the different domains of the protein will be
necessary to determine which protein domains (EGF domains,
SEA domain, and PKC phosphorylation domain) play a role in
sorting MUC13 into the parasite cytoplasm.
Under normal conditions, MUC13, like most transmembrane
mucins, functions to protect cells from infection and damage by
forming a barrier along the mucosal surface of those cells41.
However, data from our studies as well as those of others suggest
that the cellular function of MUC13 is complex, particularly when
expression is induced. However, since most of the transcriptional
changes in host cells, such as the upregulation of cellular energy
homeostasis and glucose metabolic processes and the down-
regulation of translational regulation and amino acid metabolism,
would seem to favor parasitic development, we hypothesize that
MUC13 upregulation is to the parasite’s benefit as well. However,
the knockdown or removal of MUC13 appears to not affect
parasite development (Fig. 5b). Therefore, we hypothesize a
potential role for which MUC13 in immune cell evasion. Given
the localization of MUC13 throughout the developing merosome,
it appears that MUC13 may be colocalized to the membranes of
the developing merozoites. This could represent a parasite strat-
egy to evade the host–cell immune system by covering the
parasite membrane in host–cell glycoproteins.
This strategy has been demonstrated in several other human
parasites, most notably Trypanosoma cruzi, where the parasite
surrounds itself with mucin-like glycoproteins to resemble to
confuse the host immune system48,49. Additionally, numerous
helminths, including Schistosoma mansoni, express mucin-like
molecules on their exterior to evade immune detection and aid
invasion (reviewed in ref. 50). Covering the surface of emerging
merozoites with a host glycoprotein would allow those merozoites
to more freely evade the immune system immediately after
hepatocyte rupture and allow for more efficient erythrocyte
invasion.
A final question is whether the MUC13 could be a clinically
relevant biomarker of parasite infection. MUC13 protein
expression has been implicated as a marker of several diseases,
including numerous cancers, such as gastric, ovarian and colon
cancer, inflammation and Helicobacter infection21,36,38, suggest-
ing that MUC13 may be a general signal of cellular infection.
However, these studies do not necessarily preclude the use of
MUC13 as a biomarker of Plasmodium infection for two reasons:
first, the fold-induction of MUC13 in other infectious diseases,
outside of cancer, is much smaller than observed in this study
(1.5–3 fold within the specific tissue assayed)21,36, and second, the
clinical overlap between metastatic cancer patients, where
MUC13 is often highly overexpressed, and malaria patients might
be small. Work on MUC13 in cancer has shown that it can be
detected in peripheral blood38, suggesting that this host-factor
could also potentially be used in malaria detection using per-
ipheral blood as well. In addition, because of its role in parasite
exoerythrocytic maturation, and since MUC13 is not essential
gene, at least in mice36, MUC13 might be a target for antimalarial
prophylaxis as well.
In summary, the identification of MUC13 as a new host factor
involved in parasite development will greatly enhance our
understanding of parasite liver-stage development, serve as a
valuable experimental window into exoerythrocytic development
and potentially could serve as a clinically relevant biomarker as
well.
Methods
Parasites. P. berghei-ANKA-GFP-Luc-SMCON (Pb-Luc) and P. berghei-GFP (Pb-
GFP) sporozoites were obtained by dissection of infected Anopheles stephensi
mosquito salivary glands. Dissected salivary glands were homogenized in a glass
tissue grinder and filtered twice through nylon cell strainers (20 μm pore size,
Millipore SCNY00020) and counted using a Neubauer hemocytometer. The
sporozoites were kept on ice until needed. Both Pb-Luc- and Pb-GFP-infected A.
stephensi mosquitoes were obtained from the Insectary Core Facility at New York
University.
Cell culture. HC04, Huh7.5.1, and HepG2 cells were obtained from, and initially
validated by, ATCC. Subsequently, cells were validated in study by microscopy as
all three cell lines, HepG2, Huh7.5.1, and HC04, possess quite distinct morphology.
All cell lines were cultured at 37 °C and 5% CO2 in DMEM (Invitrogen, Carlsbad,
USA) supplemented with 10% fetal bovine serum (FBS), 0.29 mg/mL glutamine,
100 units of penicillin, and 100 μg/mL streptomycin. During and after the infection,
cell medium was supplemented with antibiotics 50 μg/mL gentamycin (Gemini
Bio-Products), 50 μg/mL neomycin trisulfate salt hydrate (SIGMA), 100 units of
penicillin (SIGMA) and 100 μg/mL streptomycin (SIGMA), as well as the anti-
mycotics 50 μg/mL 5-fluorocytosine (Cayman) and 100 μg/mL posaconazole
(Cayman) were added to the media. Cell lines were tested for mycoplasma con-
tamination prior to being frozen down and new cell aliquots were used for each
replicate
Infection of hepatocytes for RNASeq and western blot. Twenty-four hour prior
to infection, hepatocytes were either seeded in 24-well (RNA extraction—120,000
per well) or 96-well plates (luciferase growth assays—30,000 per well). Hepatocytes
were infected in vitro with P. berghei sporozoites freshly dissected from infected
Anopheles stephensi mosquitoes at a ratio of 0.3 sporozoites per seeded cell. Plates
were centrifuged at 330 × g for 4 min to bring sporozoites closer to cells, and plates
were then incubated at 37 °C 5% CO2 for 2 h to promote sporozoite invasion51.
After 2 h, the cells were washed, fresh media containing 12 μM 5-fluorocytosine
(Cayman), 50 μg/ml gentamicin sulfate (Gemini Bio-Products), and 100 μg/ml
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neomycin trisulfate salt hydrate (SIGMA) was added and the cells were returned to
the incubator.
Isolation of RNA from infected and uninfected hepatocytes. Cells were dis-
sociated from plates at time zero (uninfected hepatocytes and sporozoites before
infection), 24 hpi (when the sporozoites have transformed into trophozoites), and
48 hpi (when the trophozoites have transformed into liver-stage schizonts), by the
addition of 500 μL TrypLE (Thermo Fisher Scientific), washed and resuspended in
FACS buffer (phosphate-buffered saline (PBS) supplemented with 1 mM ethyle-
nediaminetetraacetic acid, 25 mM HEPES, and 0.5% FBS), and passed through a
40 μm cell strainer (Falcon). Uninfected cells were isolated from infected cells by
FACS sorting with a BD Influx cell sorter, with gating based upon GFP mean
fluorescence intensity (MFI). Overall gating strategy is as indicated in Supple-
mentary Figure 8, with total cells identified via FSC vs. SSC (P1 gate), single cells
identified vs FSC-height vs. FSC-width and SSC-height vs. SSC-width (gates P2 and
P3), then GFP positive and negative cell collected as indicated (gates P4 and P5,
respectively). Cells were sorted directly into 600 μl Qiazol reagent (Qiagen) and
total RNA was isolated using a Qiagen miRNEasy kit (Qiagen).
Dual RNA-sequencing. Total RNA was assessed for quantity and quality using an
Agilent Tapestation. RNA libraries were generated using Illumina’s TruSeq
Stranded Total RNA Sample Prep Kit using at least 100 ng of RNA. RNA libraries
were multiplexed and sequenced with 100 base pair (bp) paired single end reads
(SR100) to a depth of approximately 25 million reads per sample on an Illumina
HiSeq2500.
Dual RNA-sequencing analysis and code availability. FastQC52 was used to
perform quality control. Raw reads were first aligned to the human genome
(GRCh38, release 25) using STAR2.5.2b53 and sorted using samtools1.254. Gene
expression was quantified using HTSeq55. Unmapped reads were extracted using
Picard tools1.141 (http://broadinstitute.github.io/picard) and aligned to P. berghei
(release 32 in PlasmoDb). Parasite gene expression was obtained using the same
workflow as the human transcripts. Differential expression analysis was performed
using DESeq256. A multifactorial design was used for the paired differential
expression analysis for both infected and noninfected samples at 48 hpi.
Gene validation (qPCR and western). For real-time qPCR, RNA was extracted as
indicated above, then converted to cDNA using superscript II (Invitrogen) and
random hexamers, according to the suggested protocol. qPCR was performed on a
Bio-Rad CFX96, using the Perfecta SYBR green master mix (Quanta) and primers
indicated in Supplementary Table 1. For western blots, Huh7.5.1 and HC04 cells
were plated at a concentration of 120,000 cells per well in a 24-well plate. After
infection and sorting as described above, 1000 infected or 100,000 uninfected cells
were washed twice with cold 1× PBS. Cells were then lysed within the plate via the
addition of 200 µl RIPA buffer (Teknova) plus 1:100 protease inhibitor (Halt—
Thermo Fisher Scientific). Equal numbers of cells, due to the low numbers of
infected cells, were loaded for protein analyses, and proteins were loaded onto
BioRad anyKD gels. Proteins were transferred to membranes and were probed with
primary anti-HsMUC13 (1:1000 Dilution from a 1 mg/ml stock, Rabbit polyclonal
—Lifespan Biosciences #LS-C345092) and α-Vinculin (1:1000 dilution from a
1mg/ml stock, Rabbit monoclonal—Abcam #ab129002) antibodies at 1:1000
dilution overnight at 4 °C, probed with goat anti-rabbit HRP secondary (1:5000
dilution from a 1 mg/ml stock, Life Technologies #G21234) and detected using
SuperSignal West Pico and Femto (4:1 ratio Pico:Femto) Chemiluminescent Sub-
strate (Thermo Fisher Scientific). Densitometry was calculated using ImageJ
(http://rsbweb.nih.gov/ij/) after image inversion and is shown relative to loading
control.
Plasmodium exoerythrocytic form culture for localization. For P. berghei ima-
ging, 96-well glass bottom plates (MatTek Corporation) were coated with poly-L-
lysine 0.01% (v/v) (SIGMA) and subsequently seeded with Huh7.5.1 or HC04 cells
(110,000 cells per well) 24 h before infection. P. berghei sporozoites were freshly
isolated from infected An. stephensi mosquitoes as above and resuspended in
DMEM media, but additionally supplemented with 0.5 μM posaconazole (Cay-
man), 12 μM 5-fluorocytosine (Cayman), 50 μg/ml gentamicin sulfate (Gemini Bio-
Products), and 100 μg/ml neomycin trisulfate salt hydrate (SIGMA). Pre-seeded
well plates were infected with P. berghei sporozoites using a 1:3 infection ratio
(sporozoite to cell) and incubated for 2 h at 37 °C in 5% CO2. After 2 h, media was
replaced and plates were incubated for 48 h.
For P. vivax imaging, P. vivax sporozoites were freshly isolated from infected
An. darlingi mosquitoes from a laboratory-established colony in the Peruvian
Amazon region43. P. vivax EEF culture was performed as follows, based upon
previous studies57. Beginning 24 h prior to mosquito dissection and infection, 8-
well Nunc Lab-Tek chamber slides (Thermo Scientific) were coated with poly-L-
lysine 0.01% (v/v) (SIGMA) and seeded with HC04 cells (45,000 cells per well).
Accudenz purified P. vivax sporozoites were diluted in antibiotics and antifungals
supplemented DMEM as above. Slides were infected using a 1:2 infection ratio
(sporozoite to HC04 cell) and incubated for 4 h at 37 °C under 5% CO2
atmosphere. After this initial incubation period, infection media was replaced, and
slides were incubated for 7 days, with cell culture media replaced every 48 h.
Plasmodium EEF and MUC13 localization and imaging. For MUC13 antibody #1
(Ab65109, AbCam), we used HC04-MUC13 wild type, HC04-MUC13 knockdown
and HC04-MUC13 knockout cells and either the P. berghei Luc or P. berghei GFP
rodent malaria parasites. We seeded the cells in 8-well chamber slides and infected
them with a ratio of 2:1 (cells/sporozoites). At 48 hpi, the cells were fixed with 4%
paraformaldehyde-PBS (Affymetrix) for 20 min at room temperature, permeabi-
lized with 0.1% tritonX-100 (SIGMA) for 10 min at room temperature, blocked
with 1% bovine serum albumin and stained overnight at 4 °C using two antibodies.
The first antibody was a UIS4 (Plasmodium berghei UIS4) goat polyclonal antibody
(dilution 1:500 from a 2mg/ml stock, LS-C204260, LifeSpan BioSciences, Inc.), the
second antibody was HsMUC13 (human Mucin 13, c-terminus region) rabbit
polyclonal antibody (dilution 1:500 from a 1mg/ml stock, Ab65109, AbCam).
Then, the following secondary antibodies and dilutions were used (1) Rhodamine
Red™-X (RRX AffiniPure Fab Fragment Bovine Anti-Goat IgG Fc fragment specific
(Jackson ImmunoResearch Lab, Inc. #805-297-008)) (dilution 1:1000) and (2)
Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG, Fc Fragment
(Jackson ImmunoResearch Lab, Inc. #111-545-046) (dilution 1:1000) for 2 h at
room temperature.
Hepatocyte plasma membrane was detected using CellMask deep red (Thermo
Fisher Scientific) at 1×. After IFA staining, chambers were removed from P.
berghei-infected Lab-Tek systems, slides were mounted with Vectashield with
DAPI (Vector Labs) and #1.5 glass coverslips were affixed using nail polish. Images
were acquired using a Zeiss LSM880 with Airyscan Confocal Microscope (63× oil
immersion lens); diode laser power was set to 5% for 405, 488, 561, and 640 nm.
Exposure values of 474 and 611 ms were used on the green and red channels,
respectively. The images were captured and processed using the confocal ZEN
software (Blue and Black edition, Zeiss).
For MUC13 antibody #2 and #3 (LifeSpan BioSciences #LS-C345092
(discontinued) and LifeSpan BioSciences #LS-A8191, respectively), we used HC04-
MUC13 wild type, HC04-MUC13 knockdown and HC04-MUC13 knockout cells
and either the P. berghei Luc or P. berghei GFP rodent malaria parasites58. Slide
chambers and 96-well plates, generated as described above, were fixed with 4%
paraformaldehyde-PBS (Affymetrix) for 20 min, permeabilized with 0.1% Triton
X-100 (SIGMA) for 5 min and stained overnight at 4 °C using one of three
antibodies. The first antibody was a HSP70 (Plasmodium heat shock protein 70)
mouse polyclonal antibody (dilution 1:500, 1 mg/ml stock), developed by GenScript
using a codon-optimized sequence of P. berghei HSP70 (PBANKA_0711900.1).
The identity of this amino acid sequence between P. berghei and P. vivax is 95%
and the antibody recognizes HSP70 from both Plasmodium species. The following
amino acid sequence was used to generate the antibody:
MVGGSTRIPK IQTLIKEFFN GKEACRSINP DEAVAYGAAV QAAILSGDQS
NAVQDLLLLD
VCSLSLGLET AGGVMTKLIE RNTTIPAKKS QIFTTYADNQ PGVLIQVYEG
ERALTKDNNL
LGKFHLDGIP PAPRKVPQIE VTFDIDANGI LNVTAVEKST GKQNHITITN
DKGRLSPEEI
DRMVNDAEKY KAEDEENKKR IEARNSLENY CYGVKSSLED QKIKEKLQPN
EVETCMKSVT
SILEWLEKNQ LAKDEYEAK QKEAEAVCSP IMSKIYQDAG AAAGGMPGGM
PGGMPGGMPG GMPGGMNFPG GMPGGMGAPA GAPAGSGPTV EEVD.
The conserved HSP70 fragment, which was codon optimized for Escherichia
coli, was expressed in E. coli, double purified, and used for mice immunization
according to GenScript protocols. The second antibody was a commercially
obtained PbUIS4 (P. berghei upregulated in infective sporozoites gene 4) goat
polyclonal antibody, used at a 1:200 dilution from 1mg/ml (Biorbyt #orb11636).
The third antibody was HsMUC13.Two additional MUC13 antibodies, one specific
for c-terminus region (rabbit polyclonal antibody, used at a 1:500 dilution from a 1
mg/ml stock—MUC13 Antibody #2—LifeSpan BioSciences #LS-C345092
(discontinued)) and a second antibody specific for the extracellular domain of
HsMUC13 (used at a 1:500 dilution from a 1mg/ml stock, MUC13 Antibody #3—
LifeSpan BioSciences #LS-A8191) were also used for confirmation, using the same
experimental conditions, in Supplementary Figure 6. All primary antibodies
concentrations were determined by performing 15 serial dilutions (1 mg/ml stock
concentration) ranging between 1:10 and 1:1 × 106 and a fixed concentration of
secondary antibodies (1.5 mg/ml stock concentration, dilution 1:500).
Once the primary antibody concentrations were optimized, 4 different
secondary dilutions, starting from a 1.5 mg/ml stock concentration were tested:
1:500, 1:600, 1:1000, and 1:1500. The following secondary antibodies and dilutions
were ultimately used: (1) Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit
IgG, Fc Fragment (Jackson ImmunoResearch Lab Inc. #111-545-008) (dilution
1:600) and (2) Alexa Fluor 647-conjugated AffiniPure Goat Anti-Mouse IgG, Fc
Fragment (Jackson ImmunoResearch Lab Inc. #111-605-008) (dilution 1:500) and
(3) Alexa Fluor 647-conjugated AffiniPure Fab Fragment Bovine Anti-Goat IgG, Fc
fragment specific (Jackson ImmunoResearch Lab Inc. # 805-607-008) (dilution
1:500). Nuclei and hepatocyte plasma membrane were detected using Hoechst
33342 (Thermo Fisher Scientific) at 500 μM and CellMask deep red (Thermo
Fisher Scientific) at 1×. After immunofluorescence staining, chambers were
removed from P. vivax infected Lab-Tek systems, slides were mounted with
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Vectashield (Vector Labs) and #1.5 glass coverslips were affixed using nail polish.
P. berghei-infected well plates were resuspended in PBS and covered with
aluminum foiled seals. Images were acquired using a PerkinElmer UltraView Vox
Spinning Disk Confocal (100× or 60× oil objective); UltraVIEW laser power was
set to 50% for 405 nm, 488 nm, 561 nm, and 640 nm. Exposure values of 474 and
611 ms were used on the green and red channel, respectively. Some 96-well plates
were also scanned using the Operetta high content imaging system (PerkinElmer)
(Supplementary Table 2).
Liver-stage P. berghei drug in vitro assay. In vitro drug assays were performed in
coated 96-well glass bottom plates (MatTek Corporation) seeded with HC04 cells
and infected with P. berghei sporozoites as previously described. Infected wells were
treated with 4-point serial 10-fold dilutions (1 μM highest concentration) of ato-
vaquone (Santa Cruz biotechnology # sc-217675) or puromycin dihydrochloride
(Santa Cruz biotechnology # sc-108071B). Independent drug treatments were
performed 2, 12, and 24 hpi. Positive controls of growth with DMSO 0.1% (v/v)
and uninfected wells were also included. Plates were incubated for 48 h, fixed with
PBS-paraformaldehyde and stained as previously described. P. berghei EEF quan-
tification was performed by indirect immunofluorescence using the Operetta High
Content Screening system (PerkinElmer). Images were collected using a 40×
objective and the acquisition parameters described in Supplementary Table 2.
Parasites EEFs, hepatocytes, and nuclei were labeled using a P.sppHSP70 mouse
polyclonal antibody (dilution 1:500, 1 mg/ml stock), HsMUC13, c-terminus region
rabbit polyclonal antibody (dilution 1:500, 1 mg/ml stock) (LifeSpan BioSciences
#LS-C345092), and Hoechst 33342, respectively. Primary antibody detection was
performed with goat anti-mouse (Alexa Fluor 647, red) and anti-rabbit (Alexa
Fluor 488, green) secondary antibodies. Images were analyzed using the Harmony
3.5 Software (PerkinElmer). Objects likely to be parasites, hepatocytes, or nuclei
were identified based on fluorescence intensity, and morphology. Cell area (μm2)
was calculated using the measure ellipse feature from Harmony.
Knockdown of MUC13. MUC13 was knocked down using an shRNA pool, con-
taining three shRNA hairpins, targeting MUC13 packaged in a lentiviral vector
(Cat # sc-45690-V, Santa Cruz Biotechnology). HC04 and Huh7.5.1 cells were
plated at 120,000 cells per well in a 24-well plate, then 24 h after plating media was
replaced with complete media (as above) plus 5 µg/ml polybrene. Virus was added
at a multiplicity of infection of 0.5, cells were spun at 800×g for 30 min, then
incubated overnight at 37 °C. The following day media was changed to complete
media and cells were again incubated overnight at 37 °C. Cells were then moved to
a 6-well plate and selected using complete media plus 2.5 µg/ml puromycin. After
7 days of selection, splitting as required, and knockdown efficiency was confirmed
via western blot.
Knockout of MUC13. MUC13 was knocked out using an single plasmid CRISPR-
Cas9 system, within the LV01 U6-gRNA:EF1a-puro-2A-CAS9-2A-tGFP, targeting
MUC13 packaged in a lentiviral vector (Sigma-Aldrich). The gRNA sequence used
was CATCTTGGCAAGGATTGCTGGG. HC04 cells were plated at 120,000 cells
per well in a 24-well plate, then 24 h later media was replaced with complete media
(as above) plus 5 µg/ml polybrene. Virus was added at a multiplicity of infection of
0.5, cells were spun at 800 × g for 30 min, then incubated overnight at 37 °C. The
following day media was changed to complete media and cells were again incu-
bated overnight at 37 °C. The following day, cells were selected for presence of the
CAS9 plasmid using complete media plus 2.5 µg/ml puromycin. After 14 days of
selection, splitting as required, cells were trypsinized and plated at an average
density of 1 cell per well in a 96-well plate in the presence of puromycin as above.
Once cells had regrown after 24 days, wells were observed via microscopy to
identify those wells which appeared to contain single colonies. The presence of
MUC13 knockout within these apparent monoclonal HC04 cell lines was assessed
first via PCR, then confirmed, after being grown up in 25 cm2 vented tissue culture
flasks, via western blot using the Abcam MUC13 rabbit polyclonal antibody
#Ab65109. Three knockout clones (clones E8, B7 and B10) were then examined
using confocal microscopy, of which two (B7 and B10) were found to have no
MUC13 signal as reported within this study.
Ethics statement. Human subject protocols were approved by the Human
Research Protection Program of the University of California San Diego (Approval
number 120652) and Universidad Peruana Cayetano Heredia (R-157-13-14).
Written informed consent was obtained from all study participants.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All RNA sequencing files were deposited in the short read sequence archive (http://
www.ncbi.nlm.nih.gov/sra) under BioProject ID PRJNA390648. The source data
for Fig. 1a is included here as Supplementary Data 3. The external source data used
to compare between our dataset and other studies in Supplementary Data 2 are
published in Tarun et al. 2008 (PMID: 18172196, PMCID: PMC2224207). All
statistics for these sequencing runs are available in Supplementary Data 1. The
authors declare that all other data supporting the findings of this study are available
within the article and its Supplementary Information files, or are available from the
authors upon request.
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